Clinical trials: Autoimmune Lymphoproliferative Syndrome
Macrophage Activation Syndrome, Secondary Hemophagocytic Lymphohistiocytosis
Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE
The purpose of this study is to assess the safety, tolerability and efficacy of emapalumab in children and adults with macrophage activation syndrome (sHLH/MAS) in Still's disease (including systemic juvenile idiopathic arthritis…
- Conditions
- Macrophage Activation Syndrome, Secondary Hemophagocytic Lymphohistiocytosis, Still Disease, Systemic Lupus Erythematosus
- Trial name
- EMERALD (NCT05001737)
- Testing
- Emapalumab
- Where
- 44 sites in United States, Belgium and 11 more
- Volunteers
- 33 people
- Sponsor
- Swedish Orphan Biovitrum
Churg-Strauss Syndrome, Eosinophilic Granulomatosis With Polyangiitis
Mepolizumab Long-term Study to Assess Real World Safety and Effectiveness of Eosinophilic Granulomatosis With Polyangiitis (EGPA) in Japan
Eosinophilic granulomatosis with polyangiitis (EGPA), formerly known as the Churg-Strauss syndrome, is a systemic necrotizing vasculitis that affects small and medium sized blood vessels.
- Trial name
- MARS (NCT04551989)
- Where
- 34 sites in Japan
- Volunteers
- 118 people
- Sponsor
- GlaxoSmithKline
Hypogammaglobulinemia, Autoimmune Conditions
Supporting Weak Immune System During Autoimmune Therapy: Testing Panzyga to Prevent Infections
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Panzyga for Prevention of Major Infection in Patients with Hypogammaglobulinemia and Autoimmune or Rheumatic…
- Conditions
- Hypogammaglobulinemia, Autoimmune Conditions, Rheumatic Conditions, Infections
- Trial name
- NCT07220915
- Testing
- Panzyga, 10% Intravenous Solution
- Where
- 25 sites in United States, Bulgaria and 5 more
- Volunteers
- 360 people
- Sponsor
- Octapharma
Churg-Strauss Syndrome, Eosinophilic Granulomatosis With Polyangiitis
Long-term Access Program (LAP) of Mepolizumab for Subjects Who Participated in Study MEA115921
Eosinophilic Granulomatosis with Polyangiitis (EGPA), also referred to as Churg-Strauss syndrome, is a rare hyper-eosinophilic syndrome.
- Trial name
- NCT03298061
- Testing
- Mepolizumab, Prednisolone
- Where
- 32 sites in United States, Belgium and 5 more
- Volunteers
- 100 people
- Sponsor
- GlaxoSmithKline
Eosinophilic Granulomatosis With Polyangiitis, Churg-Strauss Syndrome
Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis
This study will enroll male and female subjects who are 18 years of age or older with Eosinophilic Granulomatosis With Polyangiitis.
- Trial name
- NCT06046222
- Testing
- NS-229
- Where
- 34 sites in United States, Canada and 6 more
- Volunteers
- 45 people
- Sponsor
- NS Pharma, Inc.
Hematologic Malignancy, GvHD
Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
The purpose of this Phase 1, first in human open-label study is to assess the safety and tolerability of TRX-103 in patients with hematological malignancies undergoing HLA-mismatched related or unrelated hematopoietic stem cell…
- Conditions
- Hematologic Malignancy, GvHD, GVHD,Acute, GVHD, Chronic
- Trial name
- NCT06462365
- Testing
- TRX103
- Where
- 5 sites in United States
- Volunteers
- 36 people
- Sponsor
- Tr1X, Inc.
Churg-Strauss Syndrome, Eosinophilic Granulomatosis With Polyangiitis
NUCALA® Special Drug Use Investigation (EGPA, Long-term)
This study is a drug use investigation program of NUCALA. The objective of this study is to collect and assess information on the safety and effectiveness of the long-term use of NUCALA SC injection in daily clinical practice in…
- Trial name
- NCT03557060
- Testing
- Nucala
- Where
- Japan
- Volunteers
- 4,115 people
- Sponsor
- GlaxoSmithKline